La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aclarion a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aclarion..

Aclarion (NASDAQ:ACON) Azioni, Catena delle Opzioni

Aclarion

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

News

Offerings

Sherwin-Williams Announces Debt Shelf Offering; Size Not Disclosed

Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) has been in a steep rally since mid-2023. Here&#8217;s how the stock is positioned within the Adhishthana Cycle, and what that says about where it&#8217;s headed next.
<h3 class="wp-block-heading">The Phase 9 Breakout: Climb's Himalayan Ascent Begins</h3>
Under the Adhishthana Principles, stocks form a structure known as the Adhishthana Cakra between Phases 4 and 8. This is typically a channel or arc pattern. A breakout from this formation in Phase 9 signals the start of a strong bullish move, what the framework calls the Himalayan formation. Climb followed the textbook setup. 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="818" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/27092716/Climb-Monthly-Chart-Adhishthana-.png" alt="Fig.1 Climb Global Monthly Cakra Breakout (Source: Adhishthana.com)" class="wp-image-16485" style="width:474px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/27092716/Climb-Monthly-Chart-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/27092716/Climb-Monthly-Chart-Adhishthana--300x205.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/27092716/Climb-Monthly-Chart-Adhishthana--1024x698.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/27092716/Climb-Monthly-Chart-Adhishthana--768x524.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 Climb Global Monthly Cakra Breakout (Source: Adhishthana.com)</figcaption></figure>
Starting 2 Jan 2009, the stock entered Phase 4 and began forming its Cakra. This continued through Phase 8, which concluded on 31 Aug 2023. Then, right on cue, Climb broke out of the Cakra to kick off Phase 9, and the rally began.
Since then, the stock has soared by ~247%, delivering exactly what Phase 9 is known for: a decisive, powerful move.
This phase on the monthly chart will continue until 30 June 2026. After that, Climb will enter Phase 10, often the peak of the Himalayan formation. So far, the structure remains clean and bullish.
<h3 class="wp-block-heading">What About the Weekly Chart?</h3>
On the weekly chart, Climb is currently in Phase 4, which is considered a no-action zone. According to the Adhishthana framework, this phase typically offers little signal and is best observed, not traded. This weekly Phase 4 will continue until 19 April 2026.
<h3 class="wp-block-heading">Investor Outlook</h3>
Climb&#8217;s strong Phase 9 breakout on the monthly chart suggests the bullish structure is well intact. Existing investors should continue to hold, looking ahead to the potential Himalayan peak in Phase 10. New investors, however, may want to wait for more clarity, especially until the stock exits the weekly Phase 4. If the principles say no action, it&#8217;s usually for good reason.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Equities

Technicals

Opinion

Signals

Trading Ideas

CLMB

Why Climb Global Solutions Stock Keeps Climbing?

Arbe and Sensrad Sign Support and Maintenance Agreement for High-Resolution&nbsp;4D Imaging Radar Program
TEL AVIV, Israel, July 29, 2025 /PRNewswire/ -- <a href="https://arberobotics.com/">Arbe Robotics</a> Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) (TASE: ARBE), a global leader in perception radar solutions, today announced that Sensrad, a leading radar Tier-1 supplier based in Sweden, has begun delivering its first radar series powered by Arbe's chipset to customers. These radars are destined for deployment in a defense sector autonomous off-road vehicle application and in an intelligent road infrastructure project.
Sensrad recently placed a significant purchase order for Arbe chipsets, a key step toward the commercialization of its radar solutions. These chipsets will be used in multiple programs, including an initiative involving autonomous vehicles for off-road applications for a strategic US customer in the defense sector, the China-based Tianyi Transportation project, and several customer evaluations. Sensrad's progress reflects its growing commitment to expanding radar adoption across diverse verticals beyond traditional passenger automotive markets.
To accelerate the deployment Arbe and Sensrad have signed a comprehensive&nbsp;support and maintenance agreement to reinforce Sensrad's 4D Imaging Radar program built on Arbe's advanced chipset technology. Under the terms of the agreement, Sensrad will pay Arbe a recurring fee for continued support, maintenance, and professional services.
The agreement encompasses a wide range of support and maintenance services from Arbe, including design review, system debugging, calibration support, software and hardware updates, system optimization, and assistance in meeting international standards and certifications. Arbe's customer success and engineering teams will work closely with Sensrad to ensure maximum performance, reliability and efficiency across all radar systems utilizing Arbe technology.

ARBE

Arbe And Sensrad Partner To Support And Maintain High-Resolution 4D Imaging Radar Program

NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.63 by 12.7 percent. This is a 4.41 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $63.10 million which beat the analyst consensus estimate of $63.09 million by 0.02 percent. This is a 1.71 percent decrease over sales of $64.20 million the same period last year.

Earnings

Earnings Beats

NXRT

NexPoint Residential Q2 FFO $0.71 Beats $0.63 Estimate, Sales $63.10M Beat $63.09M Estimate

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) reported quarterly earnings of $0.89 per share which missed the analyst consensus estimate of $1.11 by 19.82 percent. This is a 9.88 percent increase over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $62.276 million which beat the analyst consensus estimate of $61.244 million by 1.69 percent. This is a 45.41 percent increase over sales of $42.829 million the same period last year.

Earnings Misses

Camden National Q2 Adj. EPS $0.89 Misses $1.11 Estimate, Sales $62.276M Beat $61.244M Estimate

<a href="https://www.bloomberg.com/news/articles/2025-07-29/crh-is-said-to-be-nearing-2-1-billion-deal-for-eco-material" title="https://www.bloomberg.com/news/articles/2025-07-29/crh-is-said-to-be-nearing-2-1-billion-deal-for-eco-material">https://www.bloomberg.com/news/articles/2025-07-29/crh-is-said-to-be-nearing-2-1-billion-deal-for-eco-material</a>

'CRH Is Said to Be Nearing $2.1 Billion Deal for Eco Material' - Bloomberg News

<a href="https://www.globenewswire.com/Tracker?data=sQKUxmH9nKBUVZJjI4amQo2uS5pqHO2kES7fyKd4FsZ9_8-4ybF-WjC9CMAx5at02a2rnXRyR3K9toqqaqgumA==">Immutep Limited</a> ((ASX: IMM, NASDAQ:<a href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from 6-9 September 2025.
The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company's antigen presenting cell (APC) activator, eftilagimod alfa (efti) in combination with MSD's (Merck &amp; Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA&#xAE; (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC). The global trial will enrol approximately 750 patients regardless of PD-L1 expression (Tumour Proportion Score or TPS of 0-100%) and with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries.

Biotech

General

IMMP

Immutep To Present Phase III TACTI-004 Trial Design For Efti Combo Therapy At 2025 WCLC

ABBV

AbbVie Submits U.S. FDA Approval Of Combination Treatment Of VENCLEXTA And Acalabrutinib For Previously Untreated Patients With Chronic Lymphocytic Leukemia

Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) is set to <a href="https://www.benzinga.com/quote/V/earnings">report third-quarter earnings</a> after the closing bell on Tuesday, July 29. The report follows news that Japan's Fair Trade Commission has taken its first administrative action against the credit card industry, targeting Visa Worldwide Pte Ltd.—a Singapore-based subsidiary—for alleged monopolistic practices.
Analysts expect the San Francisco-based company to report earnings of $2.85 per share, up from $2.42 per share a year ago. Revenue is projected to reach $9.85 billion, compared to $8.9 billion in the same quarter last year, according to Benzinga Pro.
Amid heightened attention on Visa, some investors are also eyeing its dividend potential. The company currently offers a dividend yield of 0.66%, paying 59 cents per share semi-annually, or $2.36 annually.
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46657015/visa-disney-blackstone-health-care-stock-on-cnbcs-final-trades">Visa, Disney, Blackstone And A Health Care Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $903,605 or around 2,542 shares. For a more modest $100 per month or $1,200 per year, you would need $180,579 or around 508 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.36 in this case). So, $6,000 / $2.36 = 2,542 ($500 per month), and $1,200 / $2.36 = 508 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
V Price Action: Shares of Visa fell 0.4% to close at $355.47 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46656981/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Pre-Market Outlook

Markets

How To Earn $500 A Month From Visa Stock Ahead Of Q3 Earnings

Independent Testing Confirms SOBRsure&#x2122; GEN 2 Capabilities, Positioning SOBRsafe for Accelerated Market Expansion
DENVER, CO / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 29, 2025 / SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) ("SOBRsafe" or the "Company"), the leader in next-generation alcohol monitoring and detection technology, today announced a significant technology milestone following comprehensive independent testing by KEA Technologies. The rigorous third-party evaluation assessed SOBRsafe's SOBRsureTM GEN 2 device across key technical parameters under controlled conditions, establishing the device as an alternative to monitor alcohol consumption in the behavioral health and wellness, and alcohol consumption and non-punitive management space.
KEA Technologies conducted extensive evaluations covering critical performance areas including calibration linearity, environmental impacts, sensitivity and drift, and trace alcohol differentiation. The testing validated the SOBRsureTM GEN 2's core sensing capabilities and consistent performance across its expected environmental operating range. The device exhibited excellent calibration linearity, demonstrating performance even with low-level ethanol underscoring the strength of SOBRsafe's early detection technology.
The device exhibited rapid ethanol response times of 30 seconds or less from initial exposure in controlled testing, including low-level, early detection scenarios. This rapid response capability, combined with the ability to differentiate trace alcohol concentrations in controlled conditions, highlights the underlying potential of SOBRsafe's monitoring and detection technology platform.

SOBR

SOBRsafe's SOBRsure GEN 2 Validated In Independent Testing, Paving Way For Market Expansion

SUUN

PowerBank's 3.79 MW Geddes Solar Project Now Operational

Early VIRTUGUIDE&#x2122; surgeons report a 30-minute reduction in surgical time versus traditional treatment1,2,&#x2A;,&#x2A;&#x2A;
WEST CHESTER, Penn., July 29, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) –&nbsp;Johnson &amp; Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4476722-1&amp;h=1828109203&amp;u=https%3A%2F%2Fwww.jnjmedtech.com%2Fen-US%2Fproduct%2Fvirtuguide-system&amp;a=VIRTUGUIDE%E2%84%A2+System">VIRTUGUIDE&#x2122; System</a>. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).3&nbsp;The system uses pre-operative planning software, developed in collaboration with PeekMed&#xAE;, to assess each patient's bunion and make personalized recommendations for the intended correction.2
Bunions are among the most common foot problems, affecting nearly one-third of adults in the U.S.4, yet traditional Lapidus surgery to treat the condition is often challenging.5,6&nbsp;The VIRTUGUIDE&#x2122; AI Lapidus System addresses this by enabling a streamlined approach and reducing surgical complexity.2&#x2A;&#x2A;&nbsp;Early users estimated procedural time savings of at least 30 minutes when using the system compared to their previous technique.1,&#x2A;

Johnson & Johnson MedTech Launches VIRTUGUIDE AI System, Cutting Bunion Surgery Time By 30 Minutes

Underscores IAS's Deep AI Integration to Analyze Billions of Transactions Daily at Scale Enabling Advertisers to Achieve Better Performance Outcomes
NEW YORK, July 29, 2025 /PRNewswire/ -- Integral Ad Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>), a leading global media measurement and optimization platform, today announced that it received the first Ethical Artificial Intelligence (AI) Certification from the Alliance for Audited Media (AAM). As the advertising and media industries continue to adopt AI to improve performance and efficiency, there is a growing need for transparency.&nbsp;This certification sets IAS apart from others in the industry for its use of AI, underscoring the company's high standards of responsible and ethical AI use across its digital ad measurement products and services.

Integral Ad Science Receives First Ethical Artificial Intelligence Certification From Alliance For Audited Media

Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) is looking for FY2026 Adj EPS of $4.50-$4.60 vs $4.68 analyst estimate. sees sales of $84.000 billion-$85.000 billion vs $84.34 billion analyst estimate.

Guidance

Sysco Sees FY2026 Adj EPS $4.50-$4.60 vs $4.68 Est; Sees Sales $84.000B-$85.000B vs $84.34B Est

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA&#xAE;, the only dual-acting IL-23 inhibitor &nbsp;&nbsp;&nbsp;
HORSHAM, Pa., July 29, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to include new evidence in the TREMFYA&#xAE; (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA).
The submission is supported by the Phase 3b APEX study in patients with active PsA, which achieved both its primary endpoint of reducing joint symptoms (ACR20) and its major secondary endpoint of inhibited progression of structural damage as measured by change in the modified van der Heijde-Sharp (vdH-S) score&nbsp;at 24 weeks, compared to placebo in bio-naïve patients. These data were <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4476905-1&amp;h=238802041&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fnew-data-show-tremfya-guselkumab-is-the-only-il-23-inhibitor-proven-to-significantly-inhibit-progression-of-joint-structural-damage-in-active-psoriatic-arthritis&amp;a=recently+presented">recently presented</a> at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress.

Johnson & Johnson Submits sBLA To FDA For TREMFYA Label Expansion In Psoriatic Arthritis

BIAF

bioAffinity Highlights Case Study On CyPath Lung Detecting Stage 1A Lung Cancer In A Patient

Funding drives operational deployment of critical infrastructure monitoring tools and deepens research-driven threat analysis capabilities
PLANO, TX / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 29, 2025 / Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) ("Intrusion" or the "Company"), a leader in cyber intelligence and threat detection, today announced it has been awarded approximately $3 million in additional funding under an existing contract with the U.S. Department of Defense (DoD). This expansion reflects the government's continued confidence in Intrusion's mission-critical role in defending national security interests through advanced cyber capabilities.
The additional funding will support ongoing research, OT Defender, Shield, and analytical services, as well as accelerate the deployment of new monitoring technologies focused on safeguarding critical infrastructure, thereby expanding the operational scope of the program.

Contracts

INTZ

Intrusion Awarded $3M To Expand DoD Cyber Defense Capabilities

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and raises the price target from $11 to $15.

Price Target

Analyst Ratings

SRPT

Piper Sandler Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $15

&nbsp;
<ul>
<li>$279.2 million in net proceeds were raised through the ATM facility this week.</li>
<li>Purchased 77,209.58 ETH, maintaining its aggressive acquisition pace.</li>
<li>Average ETH purchase price for the week was $3,756.</li>
<li>ETH holdings increased to 438,190, up 21% from the prior week's total of 360,807 ETH.</li>
<li>Cumulative staking rewards rose to 722 ETH since launch of treasury strategy on June 2, 2025.</li>
<li>ETH Concentration&#x2A; rose to 3.40 from 3.06 week over week, up 70% since launch of treasury strategy.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

SBET

SharpLink Gaming Week Ending July 27, 2025 Acquires 77,209.58 ETH

<ul>
<li>The first readout from Guardant's research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types and identified non-responders up to 5 months earlier than standard methods</li>
<li>Study shows Guardant Reveal's promise for confirming effective therapies earlier and optimizing treatment faster in patients with advanced cancer</li>
</ul>
Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), a leading precision oncology company, today announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world. The data, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnam02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Faacrjournals.org%252Fcancerrescommun%252Farticle%252Fdoi%252F10.1158%252F2767-9764.CRC-25-0151%26data%3D05%257C02%257Cmsmith%2540guardanthealth.com%257C3b94ee8022d2422e12d608ddcba80dd4%257Cea7413ad00ca45389a97fbeca4d63d79%257C0%257C0%257C638890644886571723%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DZF5ySxxMuFo1mYAmrVPODQhZ1f9sxBDIFWLdguE0jws%253D%26reserved%3D0&amp;esheet=54298183&amp;newsitemid=20250729660475&amp;lan=en-US&amp;anchor=published+today&amp;index=1&amp;md5=19aacbb65df399da821aa1e7622c2652">published today</a> in Cancer Research Communications, a journal of the American Association for Cancer Research, found that Guardant Reveal successfully detected responses to immunotherapy across multiple solid tumor types in advanced stage cancer patients and identified non-responders more than three months—and in some cases nearly five months—before disease progression was visible by standard methods.
Approximately 30% of patients with advanced-stage cancer receive immunotherapy treatment, with varying degree and duration of response. This study analyzed a large cohort of more than 500 patients with various advanced solid tumors, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers, receiving immunotherapy in a real-world setting to assess if blood-based monitoring could predict response accurately and faster than standard of care methods. The strong association found between long-term patient outcomes and changes in tumor fraction as measured with the tissue-free, methylation-based Guardant Reveal supports the use of blood-based monitoring to help predict treatment response and improve decision-making in cancer care.

Guardant Health Study Shows Blood Test Detects Immunotherapy Response Early Across Multiple Cancer Types; Guardant Reveal Identified Non-Responders Up To 5 Months Before Standard Methods, Supporting Faster, More Effective Treatment Decisions In Advanced Cancer Care.

Health Care

Press Releases

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

First Patient Enrolled in Aclarion's Groundbreaking CLARITY Trial

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

ACON

ACONW

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

Bullfrog AI Holdings, Inc. - Common Stock

Bullfrog AI Hldgs

CareCloud

CareCloud, Inc. - 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock

Comments

Aclarion

Aclarion (ACON) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO